Sign in Subscribe
Genetic research

Rapid Pain Relief for Canine Osteoarthritis Without Significant Side-Effects

Strategic Insights

— 1 min read

A novel gene-based therapy has shown significant promise in providing rapid and sustained pain relief to dogs suffering from osteoarthritis, according to a recent pilot study published in Frontiers in Veterinary Science. The trial, led by CureLab Veterinary, demonstrated that weekly injections of a p62-plasmid gene therapy, ElenaVet, resulted in a substantial reduction in chronic osteoarthritis pain, improving the quality of life for affected dogs.

Key Takeaways:

  • The pilot study involved 17 client-owned dogs with radiographically confirmed osteoarthritis, who received 1 mg intramuscular injections of ElenaVet once a week for 10 weeks.
  • The study showed a significant drop in Pain Severity Score (PSS) from 5.25 ± 3.25 and Pain Interference Score (PIS) from 7.0 ± 3.27 on the Canine Brief Pain Inventory (CBPI).
  • A remarkable 90% of dogs met the study's predefined "treatment success" criteria, which included a ≥1-point PSS drop and ≥2-point PIS drop.
  • Quality-of-life ratings improved, with 12 owners rating their dogs' quality of life as "good" or "excellent" compared to just one before treatment.
  • The first owner-noticed improvements occurred within 2-4 weeks, and scores plateaued by week 6.
  • No significant adverse events were reported during treatment, including no vomiting, diarrhea, seizures, or lab abnormalities.
  • The p62 plasmid used in ElenaVet dampens multiple inflammatory pathways simultaneously, making it a safer alternative to long-term NSAID use.
  • CureLab Veterinary has initiated discussions with the USDA Center for Veterinary Biologics (CVB) to finalize pivotal study protocols, aiming for U.S. approval within 2-3 years.

Statistics:

  • 17 client-owned dogs participated in the pilot study.
  • 90% of dogs met the study's predefined "treatment success" criteria.
  • The quality-of-life ratings improved from 1 to 12 dogs.
  • The first owner-noticed improvements occurred within 2-4 weeks.
  • The scores plateaued by week 6.
  • No significant adverse events were reported during treatment.

Sources:

  • Frontiers in Veterinary Science ( )
  • CureLab Veterinary website
  • USDA Center for Veterinary Biologics (CVB)

Read more